2025 update of the 2019 ESC/EAS guidelines for the management of dyslipidaemia. Ten key changes and their practical implications Review article
Article Sidebar
Main Article Content
Abstract
In 2025, the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS) presented updated guidelines for the management of dyslipidemia, supplementing the 2019 recommendations. This document reflects the latest advances in both cardiovascular risk assessment and lipid-lowering treatment strategies. It includes, among other things, updated SCORE2 and SCORE2-OP prediction models, an emphasis on early risk stratification and intensification of therapy in patients at high and very high risk, and an expansion of therapeutic options with new medications. The guidelines also present recommendations for the treatment of dyslipidemia in patients with HIV infection and in the oncology population. The overall document emphasizes the need for a comprehensive and personalized approach to cardiovascular disease prevention. This article presents ten key changes in the updated ESC/EAS guidelines, which have significant practical implications.
Article Details
Copyright by Medical Education. All rights reserved.
References
2. Visseren FLJ, Mach F, Smulders YM et al.; ESC National Cardiac Societies; ESC Scientific Document Group. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021; 42(34): 3227-337.
3. Csenteri O, Jancsó Z, Szöllösi GJ et al. Differences of cardiovascular risk assessment in clinical practice using SCORE and SCORE2. Open Heart. 2022; 9(2): e002087.
4. Nissen SE, Lincoff AM, Brennan D et al.; CLEAR Outcomes Investigators. Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients. N Engl J Med. 2023; 388(15): 1353-64.
5. Surma S, Romańczyk M, Filipiak KJ. Angiopoietin-like proteins inhibitors: New horizons in the treatment of atherogenic dyslipidemia and familial hypercholesterolemia. Cardiol J. 2023; 30(1): 131-42.
6. Surma S, Zembala MO, Okopień B et al. Lipoprotein (a) and lipid-lowering treatment from the perspective of a cardiac surgeon. An impact on the prognosis in patients with aortic valve replacement and after heart transplantation. Int J Cardiol Cardiovasc Risk Prev. 2024; 22: 200297.
7. Grinspoon SK, Fitch KV, Zanni MV et al.; REPRIEVE Investigators. Pitavastatin to Prevent Cardiovascular Disease in HIV Infection. N Engl J Med. 2023; 389(8): 687-99.
8. Neilan TG, Quinaglia T, Onoue T et al. Atorvastatin for Anthracycline-Associated Cardiac Dysfunction: The STOP-CA Randomized Clinical Trial. JAMA. 2023; 330(6): 528-36.